RxDoctor Payments Data

Dean Harrell, MD

Geriatric Medicine · Augusta, GANPI 1295845659

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Mylan Specialty L.p. at 29.2% of the total. Reporting peaked in 2023 at $61 and has fallen 75.7% since, to $15 in 2025. That places this record below the midpoint for geriatric medicine clinicians in GA, where the typical reported total is $150.

$196in general payments, 2019–2025

Across 12 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$57
  • Novo Nordisk$39
  • Averitas Pharma Inc.$23
  • Novartis$19
  • Radius Health, Inc.$17
  • Pfizer$15
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$196 in reported general payments places this provider in the 50th percentile of 75 geriatric medicine providers in Georgia.

See all geriatric medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$12,378
Medicare patients
127
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$24,390
JanuviaSitagliptin Phosphate20$12,544
EliquisApixaban15$8,705
XareltoRivaroxaban11$5,846
Levothyroxine Sodium47$795
Rosuvastatin Calcium34$783
Pregabalin14$763
Atorvastatin Calcium69$697
Donepezil Hcl27$693
Gabapentin26$549
Omeprazole38$505
Amlodipine Besylate60$332
Carvedilol16$315
Lisinopril41$308
Pravastatin Sodium27$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$8,70515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 75 geriatric medicine providers in Georgia.

Other geriatric medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →